Table 1:
Model Data Sources Overview
| Model Parameter | Data Source | # of model countries reported |
Reference |
|---|---|---|---|
| Cancer Cases | |||
| Diagnosed cancer cases | Estimated annual diagnosed cases by cancer type and age group | Cancer-specific: 166-178 | GLOBOCAN 20186 (see Appendix pg 7-8) |
| Stage distribution | Literature review of stage distribution at diagnosis | Cancer-specific (mean: 32, range: 3-84) | Literature review (see Appendix pg 9-49) |
| Cancer Survival | |||
| Maximum achievable survival by cancer and stage | SEER 2010-2016 5-year relative survival used as initial proxy | 1 (USA) | SEER 2010-20167 (see Appendix pg 50) |
| Survival impact of treatment/imaging modalities | Prior probabilities based on survey of expert opinions; Prior probability of needing modern modalities based on SEER 1973-2014 | NA; 1 (USA) | Expert opinion; SEER 1973-20147 (see Appendix pg 51-81) |
| Cancer Treatment | |||
| Chemotherapy availability | Reported availability of chemotherapy agents | 94 | Cohen P et al. 20198 (see Appendix pg 82-85) |
| Radiotherapy availability | Radiotherapy coverage | 173 | Atun R et al, 20159 (see Appendix pg 86-89) |
| Surgery availability | Availability of general surgery | 184 | Alkire BC et al, 201510 (see Appendix pg 90-93) |
| Targeted therapy availability | Prior probabilities set by income group | NA | (see Appendix pg 94-95) |
| Availability of imaging modalities | Availability of: - Ultrasound - X-ray - CT - MRI - PET - SPECT |
− 29 − 65 − 174 − 172 − 186 − 185 |
IAEA IMAGINE database14 (see Appendix pg 96-103) |
| Quality of care | Prior probabilities set by income group | NA | (see Appendix pg 104) |